Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC
14 Oct 2022
bởiAudrey Abella
In the long-term follow-up of the KEYNOTE-604 study, the combination regimen comprising pembrolizumab and etoposide/platinum (EP*) continued to demonstrate survival benefit as first-line therapy for patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC).
Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC
14 Oct 2022
Prexasertib works in select patients with recurrent ovarian cancer
14 Oct 2022
CHK1 inhibition with prexasertib appears to have durable activity in some patients with recurrent ovarian cancer regardless of clinical characteristics, BRCA status, or prior therapies, according to the results of a phase II trial.
